Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 228 for:    yeast

The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin:Comparing With Standardized Statin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02726555
Recruitment Status : Recruiting
First Posted : April 1, 2016
Last Update Posted : October 4, 2018
Sponsor:
Information provided by (Responsible Party):
Kangting Ji, MD, Wenzhou Medical University

Brief Summary:
Double-dose statin regimen achieves merely 6% of decrease in low-density lipoprotein cholesterol (LDL-C) levels, whereas the risk of side effects increased largely. The investigators' previous pilot study (NCT01686451) has suggested that red yeast rice was of similar lipid-lowering efficacy while was associated with less fatigue than statins. The purpose of this study is to evaluate the efficacy and safety of combined therapy with red yeast rice and low-dose atorvastatin in persons with mild atherosclerotic cardiovascular disease and who qualified for statin therapy according to national guidelines.

Condition or disease Intervention/treatment Phase
Dyslipidemia Atherosclerosis Drug: Red yeast rice and atorvastatin Drug: Atorvastatin alone Phase 3

Detailed Description:

Both Red Yeast Rice and Statins are cholesterol-lowering medications are often prescribed for secondary prevention of cardiovascular disease (CVD). The investigators' previous pilot study (NCT01686451) has suggested that red yeast rice was of similar lipid-lowering efficacy while was associated with less fatigue than statins. The aim of this study is to compare the efficacy and safety of combined therapy with red yeast rice at 1.2 g/day and atorvastatin at 10 mg/day with atorvastatin at 20 mg/day in persons with mild atherosclerotic cardiovascular disease and who qualified for statin therapy according to national guidelines.

This study will enroll individuals with established mild atherosclerotic cardiovascular disease and who do not currently take lipid-lowering medications. Participants will be randomly assigned to receive combined therapy with red yeast rice at 1.2 g/day and atorvastatin at 10 mg/day or atorvastatin at 20 mg/day for 24 weeks. Study visits will occur at screening, baseline, week 4, week 8, week 16, and week 24. Blood will be collected for laboratory testing, and standardized questionnaires will assess noncardiovascular endpoints. Pill count will be used to assess adherence of treatment. Medication side effects will be monitored and tests of alanine aminotransferase (ALT), aspartate aminotransaminase (AST) and creatine phosphate kinase (CPK) will be performed. Medication efficacy will be assessed and test of low-density lipoprotein cholesterol (LDL-C) will be performed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison Between Combined Therapy With Red Yeast Rice and Low-dose Statin and Standardized Statin: a Single-center, Non-inferiority, Randomized Clinical Trial
Study Start Date : November 2015
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Red yeast rice and atorvastatin
Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
Drug: Red yeast rice and atorvastatin
Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
Other Name: Xuezhikang; Lipitor

Active Comparator: Atorvastatin alone
Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
Drug: Atorvastatin alone
Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
Other Name: Lipitor




Primary Outcome Measures :
  1. Mean percentage change from baseline at week 24 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level [ Time Frame: Measured at screening, baseline, week 4, week 8, week 16, and week 24 ]

Secondary Outcome Measures :
  1. Mean percentage change from baseline at week 24 (or the last assessment on serum total cholesterol (TC) level [ Time Frame: Measured at screening, baseline, week 4, week 8, week 16, and week 24 ]
  2. Mean percentage change from baseline at week 24 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level [ Time Frame: Measured at screening, baseline, week 4, week 8, week 16, and week 24 ]
  3. Mean percentage change from baseline at week 24 (or the last assessment) on serum triglyceride (TG) level [ Time Frame: Measured at screening, baseline, week 4, week 8, week 16, and week 24 ]
  4. Mean percentage change from baseline at week 24 (or the last assessment) on serum non-HDL cholesterol level [ Time Frame: Measured at screening, baseline, week 4, week 8, week 16, and week 24 ]
  5. Percentage of Participants Who Experienced Statin-associated muscle symptoms (SAMs) [ Time Frame: Measured at week 4, week 8, week 16, and week 24 ]
    SAMs included all muscle-related complaints (e.g. pain, weakness, or cramps). Reported events are muscle-related complaints confirmed by an independent Clinical Events Committee (CEC) according to the nature of the muscle symptoms, the elevation in creatine kinase (CK) levels and their temporal association with statin initiation, discontinuation, and re-challenge.


Other Outcome Measures:
  1. Mean percentage change from baseline at week 24 (or the last assessment) on serum fasting blood glucose level [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
  2. Mean percentage change from baseline at week 24 (or the last assessment) on serum glycosylated hemoglobin level [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
  3. Mean percentage change from baseline at week 24 (or the last assessment) on Physical Activity Level [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Physical activity level will be estimated by short version of international physical activity questionnaire (IPAQ).

  4. Mean percentage change from baseline at week 24 (or the last assessment) on fatigue scores [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Fatigue score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  5. Mean percentage change from baseline at week 24 (or the last assessment) on Memory problems score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Memory problems score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  6. Mean percentage change from baseline at week 24 (or the last assessment) on Attention/concentration problems score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Attention/concentration problems score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  7. Mean percentage change from baseline at week 24 (or the last assessment) on Calculation problems score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Calculation problems score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  8. Mean percentage change from baseline at week 24 (or the last assessment) on Depression/hopelessness score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Depression/hopelessness score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  9. Mean percentage change from baseline at week 24 (or the last assessment) on Anxiety score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Anxiety included restless, impatience, irritability, nervous, anxious. Anxiety score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  10. Mean percentage change from baseline at week 24 (or the last assessment) on Sleep problems score [ Time Frame: Measured at baseline, week 4, week 8, week 16, and week 24 ]
    Sleep problems score is self-rated, ranging from 0-10. For the severity scale, 0=not present, 10=most severe.

  11. Safety will be assessed by the incidence of adverse events (AEs), discontinuation due to the AEs, clinically relevant changes on laboratory test results, vital signs, physical examinations, and 12-lead electrocardiograms (ECG). [ Time Frame: Screening, Baseline, Week 4, Week 8, week 16, and week 24 ]
    ECG and Physical exam only at Screening and Week 24



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with established mild atherosclerotic cardiovascular disease, defined as coronary and/or carotid and/or peripheral artery lesions <40% lumen diameter stenosis, diagnosed by coronary angiography and carotid and/or peripheral artery ultrasound respectively, together with LDL cholesterol level > 70 mg/dL (1.80 mmol/L).
  2. Female patients must be postmenopausal as defined by no menstruation for at least 12 months, or surgically sterilized for at least three months prior to beginning the study, or have a negative pregnancy test and agree to avoid pregnancy during the study and one month after the end of the study by using two reliable methods of contraception.
  3. Patients must have been informed of all aspects of the study and signed an informed consent form before any study-related activities.
  4. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

Patients who have met all the above inclusion criteria will be screened for the following exclusion criteria.

  1. Patients who have been taken lipid-lowering medications including statins or red yeast rice products during the 4 weeks prior to the screening visit.
  2. Documented history of myocardial infarction (MI), unstable angina leading to hospitalization, uncontrolled cardiac arrhythmia, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG), carotid surgery or stenting, cerebrovascular accident, transient ischemic attack, endovascular procedure or surgical intervention for peripheral vascular disease.
  3. Planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during the study.
  4. History of New York Heart Association Class III or IV heart failure within the past 12 months.
  5. Known history of hemorrhagic stroke.
  6. Patients with uncontrolled hypertension at the screening visit. Patients on stable antihypertensive medication may be enrolled provided that the medications and dosage remain stable throughout the study.
  7. Cardiovascular surgery or major operations within 6 months prior to screening visit.
  8. Patients who are taking anticoagulants except aspirin at < 325 mg/day.
  9. Patients with liver dysfunction as indicated by a serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) level of > 1.5-times of upper limit of normal (ULN) range, or clinical symptoms.
  10. Patients with elevated creatine phosphokinase level (above Upper Limit of Normal range).
  11. Patients with renal dysfunction as indicated by a serum creatinine level above ULN range, or clinical symptoms.
  12. Patients with gastric or peptic ulcer within 3 months prior to screening visit.
  13. Patients with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, or primary biliary cirrhosis. Patients on thyroid replacement therapy at stable doses may be enrolled if clinically euthyroid.
  14. Patients with clinically relevant illness within 4 weeks prior to screening visit that may interfere with the conduct of this study.
  15. Patients with a history of alcohol or narcotic substance abuse within two years prior to screening visit.
  16. Patients with hypersensitivity to lipid-lowering agents.
  17. Patients who have taken another investigational drug within 4 weeks prior to screening visit.
  18. Patients with uncontrolled metabolic or endocrine disease knowing to influence lipid values.
  19. Patients who are known to be HIV positive.
  20. Patients who have a history or presence of active malignancy (other than non-melanoma skin cancer) or clinically significant psychiatric, neurological, respiratory, hematological, or other conditions that in the opinion of investigators might interfere with or contraindicate participation of the patients in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02726555


Contacts
Layout table for location contacts
Contact: Kangting Ji, MD +8613676403180 jikt@wzmc.edu.cn

Locations
Layout table for location information
China, Zhejiang
The Second Hispital of Wenzhou Medical University Recruiting
Wenzhou, Zhejiang, China, 325000
Contact: Kangting Ji, MD    +8613676403180    jikt@wzmc.edu.cn   
Sponsors and Collaborators
Wenzhou Medical University
Investigators
Layout table for investigator information
Principal Investigator: Kangting Ji, MD The Second Hispital of Wenzhou Medical University

Layout table for additonal information
Responsible Party: Kangting Ji, MD, Professor of Medicine, Wenzhou Medical University
ClinicalTrials.gov Identifier: NCT02726555     History of Changes
Other Study ID Numbers: wzfeyxzk
First Posted: April 1, 2016    Key Record Dates
Last Update Posted: October 4, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Kangting Ji, MD, Wenzhou Medical University:
Red yeast rice
Atorvastatin
Mild cardiovascular disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Red yeast rice
Atherosclerosis
Dyslipidemias
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors